CA2371212A1 - Expression genique differente dans des regions specifiques du cerveau, dans des maladies neurodegeneratives - Google Patents

Expression genique differente dans des regions specifiques du cerveau, dans des maladies neurodegeneratives Download PDF

Info

Publication number
CA2371212A1
CA2371212A1 CA002371212A CA2371212A CA2371212A1 CA 2371212 A1 CA2371212 A1 CA 2371212A1 CA 002371212 A CA002371212 A CA 002371212A CA 2371212 A CA2371212 A CA 2371212A CA 2371212 A1 CA2371212 A1 CA 2371212A1
Authority
CA
Canada
Prior art keywords
contactin
nucleic acid
seq
sample
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002371212A
Other languages
English (en)
Inventor
Jung-Joo Hwang
K. David Becker
Robert E. Davis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Migenix Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2371212A1 publication Critical patent/CA2371212A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des molécules d'acide nucléique fonctionnant en tant qu'amorces de réaction PCR, dans la détection d'ARNm contactine, dans un échantillon. Il est possible de marquer ces molécules d'acide nucléique et de les préparer dans une trousse. L'invention concerne également un procédé de détection d'une maladie neurodégénérative, telle que la sclérose en plaques, ce procédé consistant à prélever un échantillon sur un patient, et à mesurer la quantité de protéine contactine ou d'ARNm contactine exprimée dans l'échantillon. L'invention concerne encore un procédé d'identification de patients souffrant d'une maladie neurodégénérative et susceptibles de répondre au traitement d'une telle maladie, de même que des compositions de matière comprenant une cellule isolée ou une cellule placée dans un culture qui exprime une quantité accrue ou diminuée de contactine par rapport à une cellule témoin. L'invention concerne aussi un procédé de criblage de composés, servant à mettre en évidence leur activité de réduction ou d'augmentation de l'expression de la contactine, ainsi que des compositions ou composés, notamment des compositions pharmaceutiques, identifiés à l'aide de ce procédé. On décrit encore des méthodes de traitement d'une maladie neurodégénérative à l'aide de tels composés ou compositions, ainsi que des procédés d'identification de cibles pharmaceutiques destinées à des composés modulant l'expression ou l'activité de la contactine, ainsi que des cibles identifiées à l'aide de tels procédés.
CA002371212A 1999-05-19 2000-05-19 Expression genique differente dans des regions specifiques du cerveau, dans des maladies neurodegeneratives Abandoned CA2371212A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13479099P 1999-05-19 1999-05-19
US60/134,790 1999-05-19
US57461300A 2000-05-18 2000-05-18
US09/574,613 2000-05-18
PCT/US2000/013951 WO2000070099A2 (fr) 1999-05-19 2000-05-19 Expression genique differente dans des regions specifiques du cerveau, dans des maladies neurodegeneratives

Publications (1)

Publication Number Publication Date
CA2371212A1 true CA2371212A1 (fr) 2000-11-23

Family

ID=26832668

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002371212A Abandoned CA2371212A1 (fr) 1999-05-19 2000-05-19 Expression genique differente dans des regions specifiques du cerveau, dans des maladies neurodegeneratives

Country Status (5)

Country Link
EP (1) EP1208228A2 (fr)
JP (1) JP2003504007A (fr)
AU (1) AU5150300A (fr)
CA (1) CA2371212A1 (fr)
WO (1) WO2000070099A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001069261A2 (fr) * 2000-03-15 2001-09-20 Oxford Glycosciences (Uk) Ltd. Proteines, genes et leur utilisation dans le diagnostic et le traitement de la demence vasculaire
AU2002239531A1 (en) * 2000-11-08 2002-05-27 Mitokor Differential gene expression in specific regions of the brain in neurodegenerative diseases
KR100960256B1 (ko) 2001-02-27 2010-06-01 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 유사분열 촉진인자-활성화 단백질 키나제 인산화에 근거한 알쯔하이머병 진단
EP1427858A2 (fr) 2001-09-12 2004-06-16 F. Hoffmann-La Roche Ag Marqueurs specifiques a la sclerose en plaques
EP1497661B1 (fr) * 2002-04-24 2009-11-25 EVOTEC Neurosciences GmbH Utilisation a des fins diagnostiques du gene et de la proteine ensadine-0477 pour le traitement de maladies neurodegeneratives
US20080187911A1 (en) * 2003-01-30 2008-08-07 Research Development Foundation Methods and compositions for analysis of mitochondrial-related gene expression
WO2006054979A1 (fr) * 2004-11-15 2006-05-26 Blanchette Rockefeller Neurosciences Institute Anomalies de la phosphatase 2a (pp2a) pour le diagnostic et le traitement de la maladie d'alzheimer
US20090029873A1 (en) 2005-10-11 2009-01-29 Blanchette Rockefeller Neurosciences Institute Alzheimer's Disease-Specific Alterations of the Erk1/Erk2 Phosphorylation Ratio-Alzheimer's Disease-Specific Molecular Biomarkers (Adsmb)
WO2009020058A1 (fr) * 2007-08-03 2009-02-12 Keio University Système d'administration de médicament vers une lésion de démyélinisation et marqueur biochimique de lésion de démyélinisation
ES2683021T3 (es) 2008-07-28 2018-09-24 Blanchette Rockefeller Neurosciences Institute Compuestos activadores de la PKC para el tratamiento de enfermedades neurodegenerativas
EP2669386A1 (fr) 2008-07-28 2013-12-04 Blanchette Rockefeller Neurosciences Institute Marqueurs de profil génomique induits par stimulus de la maladie d'Alzheimer
WO2011041761A1 (fr) 2009-10-02 2011-04-07 Blanchette Rockefeller Neurosciences Institute Profils de croissance de fibroblastes pour le diagnostic de la maladie d'alzheimer
EP2780316B1 (fr) 2011-11-13 2020-04-15 Blanchette Rockefeller Neurosciences Institute Esters de dcpla et méthodes de traitement les utilisant

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6017695A (en) * 1993-03-26 2000-01-25 Becton Dickinson And Company Nucleic acids encoding human cell adhesion molecule
US5888498A (en) * 1995-03-03 1999-03-30 Mitokor Cellular and animal models for diseases associated with mitochondrial defects
WO1995035373A2 (fr) * 1994-06-10 1995-12-28 La Jolla Cancer Research Foundation Molecules d'acide nucleique codant la contactine humaine
US5972693A (en) * 1995-10-24 1999-10-26 Curagen Corporation Apparatus for identifying, classifying, or quantifying DNA sequences in a sample without sequencing
NO972006D0 (no) * 1997-04-30 1997-04-30 Forskningsparken I Aas As Ny metode for diagnose av sykdommer

Also Published As

Publication number Publication date
WO2000070099A3 (fr) 2002-04-04
EP1208228A2 (fr) 2002-05-29
AU5150300A (en) 2000-12-05
JP2003504007A (ja) 2003-02-04
WO2000070099A2 (fr) 2000-11-23

Similar Documents

Publication Publication Date Title
CA2394229C (fr) Loci pour epilepsie generalisee idiopathique, leurs mutations, et methode utilisant ceux-ci pour evaluer, diagnostiquer, pronostiquer ou traiter l'epilepsie
KR101374304B1 (ko) 타입 2 당뇨병의 위험에 대한 진단 마커인 ｔｃｆ7ｌ2유전자의 유전적 변이체
AU2008286361B2 (en) IVIG modulation of chemokines for treatment of multiple sclerosis, Alzheimer's disease, and Parkinson's disease
DK2414543T3 (en) Genetic markers for risk management of atrial fibrillation and stroke
US20110251091A1 (en) Thyroid tumors identified
CA2371212A1 (fr) Expression genique differente dans des regions specifiques du cerveau, dans des maladies neurodegeneratives
CA2651376A1 (fr) Procede de diagnostic et de traitement d'une maladie mentale
EP1756317A2 (fr) Procedes d'identification de risque d'osteoarthrite et traitements associes
KR20200081380A (ko) 유전적 조절
IL179751A (en) Method for detecting the presence of autism or predisposition to autism or to an autism spectrum disorder in a subject and method for selecting biologically active compounds on autism or on autism spectrum disorder
AU785080B2 (en) Methods for identifying compounds for motion sickness, vertigo and other disorders related to balance and the perception of gravity
EP1108789A2 (fr) Quantification de l'expression de l'ARN de hTERT
KR20180088162A (ko) 노화 진단용 조성물, 이를 포함하는 키트 및 이를 진단하는 방법
US20030060617A1 (en) Aberrant glutamate transporters and methods of use
KR20220027690A (ko) 대사 증후군에 대한 정보 제공 방법 및 이를 이용한 키트
WO2021050608A1 (fr) Nouveaux marqueurs génétiques pour le syndrome de tachycardie orthostatique posturale (pots) et leurs méthodes d'utilisation pour le diagnostic et le traitement de celui-ci
AU2013276994C1 (en) IVIG Modulations of Chemokines for Treatment of Multiple Sclerosis, Alzheimer's Disease, and Parkinson's Disease
CA2400954C (fr) Procedes et compositions pour le diagnostic et le traitement de la pseudoxanthoma elasticum et des pathologies associees
US20040241712A1 (en) Diagnostic detection of nucleic acids
RU2777663C1 (ru) Количественный метод определения экспрессии аллелей GNAO1 здоровой формы и с мутацией c.607 G>A
US20030124536A1 (en) Diagnosis and treatment of vascular disease
WO2006010051A2 (fr) Methodes de diagnostic et de traitement de diabetes et de resistance a l'insuline
Class et al. Patent application title: FIBROSIS SUSCEPTIBILITY IL22RA2 GENE AND USES THEREOF Inventors: Alain Dessein (Marseille, FR) Mathieu Sertorio (Saint Ismier, FR) Laurent Argiro (Marseille, FR) Assignees: UNIVERSITE D'AIX-MARSEILLE
TW201118377A (en) Method of evaluating and predicting dementia and biological index thereof
CA2272410A1 (fr) Methode de diagnostic de l'hemochromatose hereditaire

Legal Events

Date Code Title Description
FZDE Dead